Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chitosan for AGE Reduction in Prostate Cancer
NCT03712371Phase 2Terminated
- Sponsor
- Medical University of South Carolina
- Start
- Jan 2019
- Primary completion
- Jul 2020
- Modality
- Injectable Hydrogels, Implantable Hydrogels, Biodegradable Polymers
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of chitosan in prostate cancer (PCa), sponsored by Medical University of South Carolina. Primary endpoint: Maximum Tolerated Dose at 112 days. Started Jan 2019; status: terminated.
02
Drugs
chitosan
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03712371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03712371.